Objective
Parkinson's Disease (PD) is the second most common neurodegenerative disease. The recent identification of genes underlying familial PD (alpha-synuclein and parkin) opens perspectives for a better understanding of the disease. (N) EUROPARK proposes to develop new cell culture and new animal models for PD based on these two genes using optimised lentiviral vector technology. Lentiviral vectors are efficient tools to transfer genes into the brain. Using lentiviral vector technology we will explore the role of alpha-synuclein and parkin in the pathogenesis of PD, which will enable rational development of new therapies. The potential neuroprotective role of parkin will be used as a new gene therapeutic approach. The established disease model systems will allow evaluation and validation of new gene therapeutic strategies and new drugs for the treatment of PD.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
20132 MILANO
Italy